Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 10, Pages 3346
Publisher
MDPI AG
Online
2020-10-19
DOI
10.3390/jcm9103346
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Arterial hypertension in patients under antineoplastic therapy
- (2019) Vasiliki Katsi et al. JOURNAL OF HYPERTENSION
- VEGF in Signaling and Disease: Beyond Discovery and Development
- (2019) Rajendra S. Apte et al. CELL
- Arterial hypertension in cancer: The elephant in the room
- (2019) Giacomo Tini et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- The new US and European guidelines in hypertension: A multi-dimensional analysis
- (2019) Michael Fernandes et al. Contemporary Clinical Trials
- Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients
- (2019) Rahul Aggarwal et al. HYPERTENSION
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Drug-Induced Hypertension
- (2019) Matthew C. Foy et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypertension and incident cardiovascular events following ibrutinib initiation
- (2019) Tyler Dickerson et al. BLOOD
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Roberto Iacovelli et al. Clinical Genitourinary Cancer
- Management of VEGF-Targeted Therapy-Induced Hypertension
- (2018) Stefano Caletti et al. CURRENT HYPERTENSION REPORTS
- Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population
- (2018) J. Bradford Rice et al. CURRENT MEDICAL RESEARCH AND OPINION
- VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive ProcessesNovelty and Significance
- (2018) Karla B. Neves et al. HYPERTENSION
- Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
- (2018) Avirup Guha et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction
- (2018) Kathleen W. Zhang et al. JACC-Cardiovascular Imaging
- Trends in Prevalence and Control of Hypertension According to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline
- (2018) Kirsten S. Dorans et al. Journal of the American Heart Association
- Carfilzomib-Associated Cardiovascular Adverse Events
- (2018) Adam J. Waxman et al. JAMA Oncology
- 2018 ESC/ESH Guidelines for the management of arterial hypertension
- (2018) Bryan Williams et al. EUROPEAN HEART JOURNAL
- Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
- (2018) Steven P. Treon et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study
- (2018) Kelly R. McMahon et al. PEDIATRIC NEPHROLOGY
- Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial
- (2017) Frank Ruschitzka et al. EUROPEAN HEART JOURNAL
- Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials
- (2017) Koung Jin Suh et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
- (2017) Mathias Bendtsen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Systematic Review of Strategies to Prevent Cisplatin‐Induced Nephrotoxicity
- (2017) Daniel J. Crona et al. ONCOLOGIST
- Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis
- (2017) Tingting Zhao et al. Oncotarget
- Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study
- (2016) Ajai Chari et al. BMC CANCER
- Vascular Toxicities of Cancer Therapies
- (2016) Joerg Herrmann et al. CIRCULATION
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
- (2016) Jose Luis Zamorano et al. EUROPEAN HEART JOURNAL
- Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
- (2016) Andrew J Armstrong et al. LANCET ONCOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus
- (2016) Marianne Pavel et al. Targeted Oncology
- Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis
- (2016) Xi Zhang et al. Expert Review of Clinical Pharmacology
- Hypertension in Patients with Cancer
- (2015) Vinicius Barbosa de Souza et al. Arquivos Brasileiros de Cardiologia
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies
- (2015) Jianhua Wang et al. CLINICAL DRUG INVESTIGATION
- Exposure of the Heart in Breast Cancer Radiation Therapy: A Systematic Review of Heart Doses Published During 2003 to 2013
- (2015) Carolyn W. Taylor et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
- (2015) Javid J. Moslehi et al. JOURNAL OF CLINICAL ONCOLOGY
- Large artery stiffness and hypertension after antiangiogenic drugs
- (2015) Maureen Alivon et al. JOURNAL OF HYPERTENSION
- Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
- (2015) Jean-Yves Blay et al. LANCET ONCOLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- A Randomized Trial of Intensive versus Standard Blood-Pressure Control
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age and Cancer Risk
- (2014) Mary C. White et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
- (2014) Alfredo Berruti et al. BMC CANCER
- Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis
- (2014) Wei-Xiang Qi et al. CLINICAL DRUG INVESTIGATION
- Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects
- (2014) Martin Wehling EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis
- (2013) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Heart Disease and Stroke Statistics—2014 Update
- (2013) Alan S. Go et al. CIRCULATION
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
- (2013) Sarah C. Darby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
- (2013) Kathy H. Fraeman et al. International Journal of Hypertension
- Everolimus With Reduced Tacrolimus Improves Renal Function inDe NovoLiver Transplant Recipients: A Randomized Controlled Trial
- (2012) P. De Simone et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Projections of cancer prevalence in the United Kingdom, 2010–2040
- (2012) J Maddams et al. BRITISH JOURNAL OF CANCER
- Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials
- (2012) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Endothelin 1 Activation of Endothelin A Receptor/NADPH Oxidase Pathway and Diminished Antioxidants Critically Contribute to Endothelial Progenitor Cell Reduction and Dysfunction in Salt-Sensitive Hypertension
- (2012) Dan-Dan Chen et al. HYPERTENSION
- Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation
- (2012) Robert M Langer et al. TRANSPLANT INTERNATIONAL
- Hypertension After Kidney Transplant
- (2011) Mahendra Mangray et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- The Effects of Nonsteroidal Anti-Inflammatory Drugs on Blood Pressure in Hypertensive Patients
- (2011) Stanley Snowden et al. Cardiology in Review
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin System
- (2011) Mariëtte H.W. Kappers et al. HYPERTENSION
- Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Current Targeted Therapies in Breast Cancer: Clinical Applications in the Elderly Woman
- (2011) J.-P. Spano et al. ONCOLOGIST
- Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
- (2010) V. Ranpura et al. AMERICAN JOURNAL OF HYPERTENSION
- Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors
- (2010) Emily S. Robinson et al. HYPERTENSION
- Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
- (2010) Mariëtte H.W. Kappers et al. HYPERTENSION
- Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
- (2010) Suzanne E. Dahlberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial
- (2009) Thomas M MacDonald et al. JOURNAL OF HYPERTENSION
- Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
- (2008) Xiaolei Zhu et al. ACTA ONCOLOGICA
- Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy
- (2008) J. O. Curwen et al. CLINICAL CANCER RESEARCH
- VEGF Inhibition and Renal Thrombotic Microangiopathy
- (2008) Vera Eremina et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
- (2007) J.-J. Mourad et al. ANNALS OF ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started